European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - hepatitis c, chronic - antivirals for systemic use - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults (see sections 4.2, 4.4 and 5.1). for hcv genotype specific activity, see sections 4.4 and 5.1.,

Canada - English - Health Canada

bristol-myers squibb canada - daclatasvir (daclatasvir dihydrochloride) - tablet - 30mg - daclatasvir (daclatasvir dihydrochloride) 30mg - hcv replication complex inhibitors

Canada - English - Health Canada

bristol-myers squibb canada - daclatasvir (daclatasvir dihydrochloride) - tablet - 60mg - daclatasvir (daclatasvir dihydrochloride) 60mg - hcv replication complex inhibitors

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 30mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 60mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 90mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bristol-myers squibb - daclatasvir - film-coated tablet - 60 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

spimaco, saudi arabia - daclatasvir - film-coated tablet - 60 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

spimaco - daclatasvir - film-coated tablet - 30 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

spimaco, saudi arabia - daclatasvir - film-coated tablet - 60 mg